How to design an antisense oligodeoxynucleotide experiment: A consensus approach

Antisense and Nucleic Acid Drug Development

Volumn 8, Issue 2, 1998, Pages 129-132

  Stein, C A ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE;

CONFERENCE PAPER; GENE TARGETING; PRIORITY JOURNAL;

EID: 0031923263     PISSN: 10872906     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.1.1998.8.129     Document Type: Conference Paper

References (16)

1. BENIMETSKAYA, L., BERTON, M., KOLBANOVSKY, A., BENIMETSKY, S., and STEIN, C.A. (1997a). Formation of a G-tetrad and higher order structures correlates with biological activity of the RelA (p65) "antisense" oligodeoxynucleotide. Nucleic Acids Res. 25, 2648-2656.
2. BENIMETSKAYA, L., LOIKE, J., KHALED, Z., WREIGHT, S., KAI, T., and STEIN, C.A. (1997b). Mac-1 (CD11b/CD18) is a cell surface oligodeoxynucleotide binding protein. Nature Med. 3, 414-420.
3. BENNETT, C.F. (1998). Use of cationic lipid complexes forantisense oligonucleotide delivery. In: Applied Antisense Oligodeoxynucleolide Technology. C. Stein and A. Krieg, eds. (John Wiley, New York), p. 129.
4. BENNETT, C.F., CHIANG, M.-Y., CHAN, H., and GRIMM, S. (1993). Use of cationic lipids to enhance the biological activity of antisense oligonucleotides. J. Liposome Res. 3, 85-102.
5. BENNETT. C.F., CHIANG, M.-Y., CHAN, H., SHOEMAKER, J., and MIRABELLI, C. (1992). Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol. Pharmacol. 41, 1023-1033.
6. COATS, S., FLANAGAN, W., NOURSE, J., ROBERTS, J., and KERBEL, R. (1996). Requirement of p27kip1 for restriction point control of the fibroblast cell cycle. Science 272, 877-880.
7. DEAN, N., and McKAY, R. (1994). Inhibition of protein kinase C-α expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA 91, 11762-11766.
8. DEAN, N., McKAY, R., CONDON, T., and BENNETT, C.F. (1994). Inhibition of protein kinase C-α expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters. J. Biol. Chem. 269, 16416-16424.
9. ECKSTEIN, F. (1985). Nucleoside phosphorothioates. Annu. Rev. Biochem. 54, 367-402.
10. GAO, W., HAN, F., STORM, C., EGAN, W., and CHENG, Y.C. (1992). Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNAse H: Implications for antisense technology. Mol. Pharmacol. 41, 223-229.
11. GEWIRTZ, A., and CALABRETTA, B. (1998). A c-myb antisense oligodeoxynucleotide inhibits normal human hematopoiesis in vitro. Science 242, 1303-1306.
12. GILES, R., SPILLER, D., and TIDD, D. (1993). Chimeric oligodeoxynucleotide analogues: Enhanced cell uptake of structures which direct ribonuclease H with high specificity. Anti-Cancer Drug Design 8, 33-51.
13. GILES, R., and TIDD, D. (1992a). Enhance RNase H activity with methylphosphonodiester/phosphodiester chimeric antisense oligodeoxynucleotides. Anti-Cancer Drug Design 7, 37-48.
14. GILES, R., and TIDD, D. (1992b). Increased specificity for antisense oligodeoxynucleotide targeting of RNA cleavage by RNAse H using chimeric methylphosphonodiester/phosphodiester structures. Nucleic Acids Res. 20, 763-770.
15. GUGA, P., KOZIOLKIEWICZ, M., OKRUSZEK, A., and STEC, W. (1998). Oligo(nucleoside phosphorothioate)s. In: Applied Antisense Oligonucleotide Technology. C. Stein and A. Krieg, eds. (John Wiley, New York), p. 23.
16. HIGGINS, K., PEREX, J., COLEMAN, T., DORSHKIND, K., McCOMAS, W., SARMIENTO, U., ROSEN, C., and NARAYANAN, R. (1993). Antisense inhibition of the p65 subunity of NF-κB blocks tumorigenicity and causes tumor regression. Proc. Natl. Acad. Sci. USA 90, 9901-9905.